Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Gilead Sciences, Inc.
32 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
M&A
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
PR-M06-20-NI-028
Partnership
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
PR-M05-20-NI-041
COVID-19 Treatment
Mylan to Supply Investigational Antiviral Remdesivir for the Potential Treatment of COVID-19
PR-M05-20-NI-018
Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials
PR-M04-20-NI-003
M&A
Gilead to Acquire Forty Seven for $4.9 Billion
PR-M03-20-NI-003
Coronavirus
Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
PR-M02-20-NI-037
Coronavirus
Gilead Sciences Begins Trial on Treatment for Coronavirus (2019-nCoV)
PR-M02-20-NI-003
Licensing
Gilead Licenses Antiviral Candidates from Novartis
PAO-M08-19-NI-019
Collaboration
Gilead and Galapagos Enter Into Transformative Research and Development Collaboration
PR-M07-19-NI-046
Capacity Expansion
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
PR-M07-19-NI-043
Announcement
AbCellera Announces Therapeutic Antibody Discovery Collaboration with Gilead in Infectious Disease
PR-M06-19-NI-017
Appointment
Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer
PR-M05-19-NI-081
HIV
Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic
PR-M05-19-NI-038
Leadership
Changes Coming to Gilead Under New Top Exec
PAO-M05-19-NI-016
Financial Results
Gilead Sciences Announces First Quarter 2019 Financial Results
PR-M05-19-NI-018
Milestone Payment
Agenus Milestone Triggers $7.5M Payment from Gilead
PR-M03-19-NI-047
Immuno-oncology
Gilead Invests in Immuno-oncology
PAO-M01-19-NI-001
Appointment
Roche Exec Moves to Gilead
PAO-M12-18-NI-010
Collaboration
TARGET PharmaSolutions® to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead Sciences
PR-M11-18-NI-089
Generics
Gilead Makes Move to Launch Early Generics
PAO-M10-18-NI-001
HIV Diagnoses
Gilead Announces New Data on the Impact of Truvada® for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States
PR-M07-18-NI-087
Inflammatory Disease
Gilead Sciences and Verily Life Sciences LLC Enter Collaboration, Hope to Better Understand Inflammatory Diseases
PAO-M05-18-NI-002
Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope
PR-M03-18-NI-021
Appointment
Gilead Sciences Announces Senior Management Change
PR-M02-18-NI-101
1
2
»
